Seagen Talks Up 24% Growth, Not About Speculated Merck Buyout

Daiichi Arbitration Is Another Wildcard

 
• By Alaric DeArment

The Seattle-based biotech reported a 24% increase in product sales in the second quarter amid speculation that Merck is about to acquire the company.

Like Merck before it, Seagen kept quiet about a speculated buyout deal between the two companies • Source: Shutterstock

More from Earnings

More from Business